Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 999
- Registration Number
- NCT06858878
- Locations
- 🇺🇸
Alliance for Multispecialty Research Mobile, Mobile, Alabama, United States
🇺🇸Gilbert Center for Family Medicine, Gilbert, Arizona, United States
🇺🇸Desert Clinical Research, Mesa, Arizona, United States
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
- Conditions
- Obesity
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 200
- Registration Number
- NCT06761703
- Locations
- 🇺🇸
YourBio Health/CRT, Medford, Massachusetts, United States
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 844
- Registration Number
- NCT06747949
- Locations
- 🇺🇸
Tufts University School of Dental Medicine, Boston, Massachusetts, United States
🇦🇷DOM Centro de Reumatología, Ciudad Autónoma de Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina
🇯🇵Hospital of the University of Occupational and Environmental Health, Japan, Kita Kyushu-shi, Hukuoka, Japan
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 240
- Registration Number
- NCT06745323
- Locations
- 🇧🇷
Cipo - Centro Integrado de Pesquisa em Oncologia, Porto Alegre, Rio Grande Do Sul, Brazil
🇨🇳Shanxi Bethune Hospital, Taiyuan, Shanxi, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
- Conditions
- Relapsing-remitting Multiple Sclerosis (RRMS)
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 444
- Registration Number
- NCT06700343
- Locations
- 🇺🇸
University of South Alabama, Mobile, Alabama, United States
🇺🇸Profound Research - Neurology Center of Southern California, Carlsbad, California, United States
🇺🇸Mountain Neurological Research Center, Basalt, Colorado, United States
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 675
- Registration Number
- NCT06691984
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Providence Saint Jude Medical Center, Fullerton, California, United States
🇺🇸University of California Irvine, Irvine, California, United States
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 44
- Registration Number
- NCT06674941
- Locations
- 🇺🇸
PPD Development, LP, Las Vegas, Nevada, United States
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 409
- Registration Number
- NCT06660173
- Locations
- 🇺🇸
Accel Research Site - Birmingham Clinical Research Unit, Birmingham, Alabama, United States
🇺🇸Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸Hope Clinical Research LLC, Canoga Park, California, United States
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 10
- Registration Number
- NCT06649006
- Locations
- 🇯🇵
Akita University Hospital, Akita-shi, Akita, Japan
🇯🇵Kyushu University Hospital, Fukuoka-shi, Fukuoka, Japan
🇯🇵Kurume University Hospital, Kurume-shi, Fukuoka, Japan
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
- First Posted Date
- 2025-05-27
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Amgen Inc.
- Target Recruit Count
- 3
- Registration Number
- 2025-520503-27-00
- Locations
- 🇧🇪
Emmaues, Mechelen, Belgium